By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Best Place To BuildGrowing Organs in a Petri Dish and Starting Labs in IIT Madras | Dr Anubama Rajan
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Organoids, drug discovery, and building IIT Madras’s new med-tech department
- Dr. Anubama Rajan describes organoids as 3D stem-cell-derived “mini organs” that replicate key human organ functions in a dish, enabling more human-relevant biology than cancer cell lines or many animal models.
- She argues organoids can reduce costly drug-development failure by improving translational relevance, noting that over 90% of drugs fail at the clinical trial stage partly due to poor preclinical models.
- Her research uses patient-derived airway/lung organoids to study respiratory disease mechanisms in Indian populations, including how viral infections can trigger or worsen asthma/COPD-like conditions.
- She recounts spearheading COVID-era biosafety level-3 (BSL-3) protocol development for studying coronavirus infection in organoid models, highlighting the intensity and regulatory complexity of high-containment work.
- The conversation also outlines IIT Madras’s new Medical Sciences & Technology department: interdisciplinary programs (BS, MS, PhD, MD-PhD), hospital immersions, clinician participation, and a translation-first Centre of Excellence for Diabetes Research focused on usable tools/technologies.
IDEAS WORTH REMEMBERING
5 ideasOrganoids are a bridge between simplistic cell lines and imperfect animal models.
Because organoids are derived from organ-specific stem cells (not cancer cell lines), they can reproduce functional behaviors (e.g., mucus production, cilia beating, fluid swelling) that better approximate human physiology.
Better preclinical models can directly impact drug-development economics.
Rajan links the massive late-stage failure rate (>90% at clinical trials) to non-translational preclinical evidence; organoids are positioned as a way to test efficacy/toxicity in a more human-relevant system earlier.
Patient-derived organoids enable population- and phenotype-specific research.
By generating organoids from patient biopsies (plus healthy controls), labs can model diseases and triggers (e.g., viral infection exacerbating asthma/COPD) in ways that reflect local genetics, exposures, and comorbidities.
High-containment virology requires infrastructure and protocol leadership, not just lab skills.
During COVID, coronavirus research demanded BSL-3 conditions (negative pressure, permissions, surveillance), and Rajan’s role centered on creating workable organoid-based protocols within those constraints.
Returning to India can be strategically viable if you bring a distinctive capability.
She intentionally moved from gut to airway organoids because gut organoid work had already reached India; her plan was to “bring something new to the table” that matched India’s respiratory disease burden.
WORDS WORTH SAVING
5 quotesOrganoids… are nothing but three-dimensional bunch of stem cells that can be grown in a dish to mimic physiology of organs.
— Dr. Anubama Rajan
From the lab to the market, we spend billions of dollars… More than 90% of the drug fails at clinical trial.
— Dr. Anubama Rajan
You can’t study a human disease in a monkey or a rat because the symptoms are very different.
— Dr. Anubama Rajan
It’s not about how much you publish, where you publish. It’s always about what are you going to bring to the table.
— Dr. Anubama Rajan (recounting Dr. Cherry Kang’s advice)
When I started… there was no lab, no name board, no phone, no laptop, nothing… But… the path that they showed me was so striking that I wanted to do it.
— Dr. Anubama Rajan
High quality AI-generated summary created from speaker-labeled transcript.
